Chromomycosis (Chromoblastomycosis): A Patient Guide
At a Glance
Chromoblastomycosis is a slow-growing, noncontagious fungal infection acquired when soil- or plant-associated fungi enter broken skin. Treatment often requires months of antifungal medicine, sometimes surgery or cryotherapy, plus long-term follow-up for recurrence and unusual skin changes.
Chromomycosis, more accurately known as chromoblastomycosis, is a chronic and deeply persistent fungal infection of the skin and underlying tissue. It typically begins when a specific group of dark-walled fungi, found naturally in soil and plant matter, enters the body through a minor injury—such as a splinter, a thorn prick, or a small scrape. Because it is most common among people who work closely with the land in tropical and subtropical climates, it is often considered an occupational condition for farmers, gardeners, and agricultural workers [1][2].
Importantly, this is an environmental infection. It is not contagious and is not ordinarily spread by casual person-to-person contact.
The defining characteristic of this infection is the way the fungus adapts once it is inside the human body. It transforms into thick-walled, chestnut-brown structures called muriform cells (or sclerotic bodies). These specialized cells are exceptionally hardy; their structure helps them resist the body’s natural immune defenses, allowing them to survive deep within the skin for years. This biological resilience is why the condition does not resolve on its own and why it is known for its very slow, progressive growth that can span decades [3][4].
Living with chromoblastomycosis requires patience and a long-term perspective on health. Because the fungus is so well-protected, treatment is highly individualized. While some small, early lesions might be completely removed with surgery, more extensive disease usually requires a combination of long-term systemic antifungal medications (often for many months or longer) and clinician-guided physical therapies like surgery or cryotherapy [5][6].
Even after the skin has appeared to heal, the potential for the fungus to hide in scar tissue means that long-term monitoring remains a cornerstone of care. Staying connected with your medical team allows for the early detection of any recurrence and helps manage the risk of more serious skin changes, such as squamous cell carcinoma, which can arise in chronic infections. By staying informed and proactive, you can effectively manage this condition and protect your long-term health and mobility [7][8].
In this guide
6 chapters
Understanding Chromoblastomycosis
Learn how chromoblastomycosis starts, why diagnosis can take years, which tests identify it, and how chronic infection may cause scarring, swelling, or skin cancer.
Signs and Symptoms of Chromoblastomycosis
Learn how chromoblastomycosis symptoms change over time, including warty lesions, itching, swelling, pain, drainage, and signs that need medical review.
How Chromoblastomycosis is Diagnosed
Learn how chromoblastomycosis is diagnosed with KOH scraping, skin biopsy, fungal culture, PCR, pathology terms, and tests for look-alike conditions too.
Treating Chromoblastomycosis: A Long-Term Strategy
Learn how chromoblastomycosis treatment uses surgery, oral antifungals, physical therapies, liver monitoring, and long-term follow-up to help limit relapse.
Daily Care and Warning Signs
Learn daily chromoblastomycosis wound care, infection warning signs, skin cancer changes, lymphedema symptoms, and when prompt medical evaluation is needed.
Long-Term Health and Monitoring
Learn how to monitor chromoblastomycosis after treatment, recognize relapse and skin cancer warning signs, and manage scarring, swelling, and follow-up care.
Common questions in this guide
How is chromoblastomycosis diagnosed?
Can chromoblastomycosis spread from one person to another?
Why does chromoblastomycosis take so long to treat?
What treatments are available for chromoblastomycosis?
Can chromoblastomycosis come back after it seems healed?
What skin changes should I watch for during follow-up?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Chromomycosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How do we definitively distinguish my condition from other common skin infections?
- 2.What is the most effective treatment approach for the specific size and stage of my lesion?
- 3.How will we measure whether my treatment is working over the coming months?
- 4.What specific signs of secondary infection or unusual changes should I watch for daily?
- 5.What long-term follow-up plan do you recommend to ensure the infection does not return?
References
References (8)
- 1
Chromoblastomycosis.
Queiroz-Telles F, de Hoog S, Santos DW, et al.
Clinical microbiology reviews 2017; (30(1)):233-276 doi:10.1128/CMR.00032-16.
PMID: 27856522 - 2
The global burden of chromoblastomycosis.
Santos DWCL, de Azevedo CMPES, Vicente VA, et al.
PLoS neglected tropical diseases 2021; (15(8)):e0009611 doi:10.1371/journal.pntd.0009611.
PMID: 34383752 - 3
In Vitro Activities of Five Antifungal Drugs Against Conidia and Sclerotic Cells of Chromoblastomycosis Agent Fonsecaea spp.
Takahashi AB, Grisólia DPA, Silva MBD, et al.
Microbiology and immunology 2026; (70(3)):139-147 doi:10.1111/1348-0421.70038.
PMID: 41457406 - 4
Chromoblastomycosis in Latin America and the Caribbean: Epidemiology over the past 50 years.
Guevara A, Siqueira NP, Nery AF, et al.
Medical mycology 2021; (60(1)) doi:10.1093/mmy/myab062.
PMID: 34637525 - 5
CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE.
Queiroz-Telles F
Revista do Instituto de Medicina Tropical de Sao Paulo 2015; (57 Suppl 19()):46-50.
PMID: 26465369 - 6
[Management of chromoblastomycosis, a challenge for limited-resource countries such as Madagascar].
Sendrasoa FA, Rakotoarisaona MF, Ranaivo IM, et al.
Annales de dermatologie et de venereologie 2020; (147(5)):377-382 doi:10.1016/j.annder.2020.01.018.
PMID: 32220474 - 7
Squamous cell carcinoma in chronic lesions of recalcitrant chromoblastomycosis. Study of ten patients treated at the Dermatological Center of Yucatán, Mexico.
Calderón Quiroz ER, Torres Guerrero E, Proy Trujillo H, et al.
Anais brasileiros de dermatologia 2026; (101(4)):501372 doi:10.1016/j.abd.2026.501372.
PMID: 42235130 - 8
Chromoblastomycosis is curable with DAT therapy (debulking, intralesional amphotericin B, oral terbinafine); case series of 16 patients.
Ranawaka RR, Abeywickrama V
Indian journal of pharmacology 2024; (56(6)):437-439 doi:10.4103/ijp.ijp_397_24.
PMID: 39973833
This page is for informational purposes only and does not constitute medical advice. A clinician should confirm the diagnosis and tailor antifungal treatment, surgery, and follow-up to your lesion.